Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.

Nan H, Qureshi AA, Hunter DJ, Han J.

Cancer Causes Control. 2009 Mar;20(2):171-9. doi: 10.1007/s10552-008-9231-9. Epub 2008 Sep 24.

2.

Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk.

Nan H, Qureshi AA, Hunter DJ, Han J.

Br J Dermatol. 2008 Aug;159(2):314-21. doi: 10.1111/j.1365-2133.2008.08624.x. Epub 2008 May 28.

3.

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.

Wan Y, Wu W, Yin Z, Guan P, Zhou B.

BMC Cancer. 2011 May 29;11:208. doi: 10.1186/1471-2407-11-208.

4.

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.

Clin Cancer Res. 2007 Jul 15;13(14):4123-9.

5.

Association of breast cancer outcome with status of p53 and MDM2 SNP309.

Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S.

J Natl Cancer Inst. 2006 Jul 5;98(13):911-9.

PMID:
16818855
6.

The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.

Almquist LM, Karagas MR, Christensen BC, Welsh MM, Perry AE, Storm CA, Nelson HH.

Carcinogenesis. 2011 Mar;32(3):327-30. doi: 10.1093/carcin/bgq256. Epub 2010 Dec 1.

7.

MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.

Dong HJ, Fang C, Fan L, Zhu DX, Wang DM, Zhu HY, Zhuang Y, Miao KR, Liu P, Xu W, Li JY.

Int J Cancer. 2012 May 1;130(9):2054-61. doi: 10.1002/ijc.26222. Epub 2011 Aug 9.

8.

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.

Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, Wake N.

Oncol Rep. 2013 Jul;30(1):25-34. doi: 10.3892/or.2013.2433. Epub 2013 Apr 29.

9.

No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.

Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Försti A, Kumar R.

Br J Dermatol. 2007 Aug;157(2):375-7. Epub 2007 Jun 6.

PMID:
17553029
10.

MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.

Capasso M, Ayala F, Avvisati RA, Russo R, Gambale A, Mozzillo N, Ascierto PA, Iolascon A.

J Hum Genet. 2010 Aug;55(8):518-24. doi: 10.1038/jhg.2010.62. Epub 2010 Jun 10.

PMID:
20535124
11.

Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Yu H, Huang YJ, Liu Z, Wang LE, Li G, Sturgis EM, Johnson DG, Wei Q.

Mol Carcinog. 2011 Sep;50(9):697-706. doi: 10.1002/mc.20806. Epub 2011 Jun 7.

12.

Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.

Zhang JN, Yi SH, Zhang XH, Liu XY, Mao Q, Li SQ, Xiong WH, Qiu YM, Chen T, Ge JW.

Genet Mol Res. 2012 Oct 4;11(4):3618-28. doi: 10.4238/2012.October.4.9.

13.

Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

Walsh CS, Miller CW, Karlan BY, Koeffler HP.

Gynecol Oncol. 2007 Mar;104(3):660-4. Epub 2006 Nov 21.

PMID:
17123590
14.

Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.

Chien WP, Wong RH, Cheng YW, Chen CY, Lee H.

Ann Surg Oncol. 2010 Apr;17(4):1194-202. doi: 10.1245/s10434-009-0853-2. Epub 2009 Nov 26.

PMID:
19941079
15.

MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.

Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ, Chang KW.

Radiother Oncol. 2008 May;87(2):243-52. doi: 10.1016/j.radonc.2008.03.018. Epub 2008 Apr 16.

PMID:
18423915
16.

Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.

Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC, Lee YJ.

Oncol Rep. 2011 Jun;25(6):1755-63. doi: 10.3892/or.2011.1254. Epub 2011 Apr 8.

PMID:
21479369
17.

MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.

Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Lee CP, Lin SF.

Mol Carcinog. 2014 Dec;53(12):951-9. doi: 10.1002/mc.22061. Epub 2013 Jul 2.

PMID:
23818300
18.

Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians.

Nan H, Kraft P, Hunter DJ, Han J.

Int J Cancer. 2009 Aug 15;125(4):909-17. doi: 10.1002/ijc.24327.

19.

Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.

Duan X, Li J.

Medicine (Baltimore). 2017 Sep;96(36):e7856. doi: 10.1097/MD.0000000000007856.

20.

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.

Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I.

J Clin Oncol. 2008 May 10;26(14):2252-7. doi: 10.1200/JCO.2007.11.5212.

PMID:
18467716

Supplemental Content

Support Center